by Truveta Research | Aug 31, 2023 | Research, Research Insights
Compared to July, Truveta Data shows a 70.1% increase in the rate of COVID-19 positive tests and a 74.1% increase in the percentage of hospitalizations associated with COVID. Compared to 7 days prior, we see an 11.2% increase in the rate of COVID positive tests and an...
by Truveta Research | Aug 23, 2023 | Research, Research Insights
The United States has some of the highest rates of adverse maternal health outcomes compared to other high-income countries (Creanga et al., 2015; Gunja et al., 2022; Taylor et al., 2022). These outcomes have only increased in the last decade (Hoyert, 2023; U.S....
by Truveta Research | Jul 10, 2023 | Research, Research Insights
We explored the demographic characteristics of patients with type 2 diabetes mellitus, heart failure, and chronic kidney disease who received a prescription for empagliflozin (Jardiance) and/or dapagliflozin (Farxiga), two commonly used SGLT2i drugs. We saw...
by Truveta Research | Jun 6, 2023 | Research, Research Insights
Beginning in Fall 2022, the news media has reported extensively on the use of Glucagon-like peptide-1 receptor agonist (GLP-1s) for weight loss (Belluz, 2023). Physicians have taken to TikTok to promote GLP-1s for weight loss, and celebrities & influencers – such...
by Truveta Research | May 11, 2023 | News, Research, Research Insights
Today Truveta announced a new research letter published in JAMA Network Open using de-identified patient data from Truveta Studio. Published in collaboration with Anupam B. Jena, MD, PhD and Christopher M Worsham, MD, MPH from Harvard University, the new research...
by Truveta Research | May 9, 2023 | Research, Research Insights
This blog is an extension of our poster presented at ISPOR, titled Real-World Effectiveness of SGLT2 Inhibitors Vs Metformin as First-Line Therapy in Type 2 Diabetes. Individuals with type 2 diabetes mellitus (T2DM) have a higher risk of cardiovascular disease...
